idazoxan has been researched along with ketamine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Delima, EC; Rietkerk, FE | 1 |
Arianna, M; Franco, M; Gentile, L; Luca, R; Roberta, L | 1 |
García-Fuster, MJ; García-Sevilla, JA | 1 |
1 trial(s) available for idazoxan and ketamine
Article | Year |
---|---|
IMMOBILIZING THE VULNERABLE APENNINE CHAMOIS (RUPICAPRA PYRENAICA ORNATA) WITH A LOW-DOSE XYLAZINE-KETAMINE COMBINATION, REVERSED WITH IDAZOXAN OR ATIPAMEZOLE.
Topics: Adrenergic alpha-2 Receptor Antagonists; Anesthetics, Dissociative; Animals; Animals, Wild; Animals, Zoo; Drug Therapy, Combination; Female; Hypnotics and Sedatives; Idazoxan; Imidazoles; Immobilization; Ketamine; Male; Rupicapra; Xylazine | 2015 |
5 other study(ies) available for idazoxan and ketamine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Clinical and haematological changes in gazelles during xylazine/ketamine anaesthesia and following reversal with RX-821002A.
Topics: Adrenergic alpha-Antagonists; Anesthesia; Animals; Antelopes; Blood Cell Count; Dioxanes; Hemodynamics; Idazoxan; Injections, Intravenous; Ketamine; Male; Xylazine | 1994 |
Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Apoptosis; Autoreceptors; Blotting, Western; Brain; CASP8 and FADD-Like Apoptosis Regulating Protein; Cerebral Cortex; Clorgyline; Desipramine; Electroshock; Excitatory Amino Acid Antagonists; Fas-Associated Death Domain Protein; Fluoxetine; Idazoxan; Indans; Ketamine; Male; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Phosphoproteins; Phosphorylation; Rats; RNA-Binding Proteins; Thiazoles | 2016 |